Document is current
Any future updates will be listed below
-
Authors
Arafeh, Rand https://orcid.org/0000-0001-7107-2982
Shibue, Tsukasa https://orcid.org/0000-0002-3665-6154
Dempster, Joshua M. https://orcid.org/0000-0002-3634-9576
Hahn, William C. https://orcid.org/0000-0003-2840-9791
Vazquez, Francisca https://orcid.org/0000-0002-2857-4685
- License Information
-
More Information
Article History
Accepted: 24 September 2024
First Online: 28 October 2024
Competing interests
: R.A. and T.S. declare no competing interests. J.M.D. is a consultant for and holds equity in Jumble Therapeutics. F.V. receives research support from the Dependency Map Consortium, Riva Therapeutics, Bristol Myers Squibb, Merck, Illumina and Deerfield Management; is on the scientific advisory board of GSK; is a consultant and holds equity in Riva Therapeutics; and is a co-founder and holds equity in Jumble Therapeutics. W.C.H. is a consultant for Thermo Fisher, Solasta Ventures, KSQ Therapeutics, Jubilant Therapeutics, Function Oncology, RAPPTA Therapeutics, Serinus Biosciences, Riva Therapeutics, Kestrel Therapeutics, Frontier Medicines and Calyx.
